Karyopharm Therapeutics (KPTI) Current Deferred Revenue (2012 - 2020)
Karyopharm Therapeutics' (KPTI) quarterly Current Deferred Revenue came in at $297000.0 in Q4 2020, down 87.31% YoY from $2.3 million in Q1 2020, and little changed on a QoQ basis from $297000.0 in Q3 2020.
Karyopharm Therapeutics (KPTI) Current Deferred Revenue (2012 - 2020) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 9 years of Current Deferred Revenue data on file, last reported at $297000.0 in Q4 2020.
- Quarterly Current Deferred Revenue fell 87.31% year-over-year to $297000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $297000.0 (down 87.31% YoY) and the FY2020 annual result came in at $297000.0, down 87.31% from the prior year.
- Current Deferred Revenue held at $297000.0 in Q4 2020, from $297000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $21.9 million in Q4 2017 to a low of $189000.0 in Q2 2018.
- A 5-year average of $3.7 million and a median of $344000.0 in 2017 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2017 — Current Deferred Revenue jumped 7728.93% — and 2018, when it plunged 98.22%.
- Tracing KPTI's Current Deferred Revenue over 5 years: stood at $280000.0 in 2016, then jumped by 7728.93% to $21.9 million in 2017, then sank by 98.22% to $390000.0 in 2018, then surged by 500.26% to $2.3 million in 2019, then tumbled by 87.31% to $297000.0 in 2020.
- The last three Current Deferred Revenue figures came in at $297000.0 (Q4 2020), $297000.0 (Q3 2020), and $297000.0 (Q2 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 297,000.00 |
| Sep 30, 2020 | 297,000.00 |
| Jun 30, 2020 | 297,000.00 |
| Mar 31, 2020 | 3.48 Mn |
| Dec 31, 2019 | 2.34 Mn |
| Sep 30, 2019 | 1.05 Mn |
| Jun 30, 2019 | 1.29 Mn |
| Mar 31, 2019 | 10.65 Mn |
| Dec 31, 2018 | 390,000.00 |
| Sep 30, 2018 | 9.36 Mn |
| Jun 30, 2018 | 189,000.00 |
| Mar 31, 2018 | 19.73 Mn |
| Dec 31, 2017 | 21.92 Mn |
| Sep 30, 2017 | 298,000.00 |
| Jun 30, 2017 | 1.03 Mn |
| Mar 31, 2017 | 286,000.00 |
| Dec 31, 2016 | 280,000.00 |
| Sep 30, 2016 | 275,000.00 |
| Jun 30, 2016 | 269,000.00 |
| Mar 31, 2016 | 263,000.00 |